{
    "organizations": [],
    "uuid": "747f7ecd27b46e3671fbebc5c92330a4b667a9db",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-living-cell-technologies-to-sell-5/brief-living-cell-technologies-to-sell-50-pct-stake-in-jv-for-3-mln-idUSFWN1PJ1AQ",
    "ord_in_thread": 0,
    "title": "BRIEF-Living Cell Technologies To Sell 50 Pct Stake In JV For $3 Mln",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 25 (Reuters) - Living Cell Technologies Ltd:\n* AGREED TO SELL ITS 50% SHAREHOLDING IN DIATRANZ OTSUKA LIMITED TO OTSUKA PHARMACEUTICAL FACTORY FOR $3 MILLION​\n* CO AND DOL TO SIGN MOU TO EXCLUSIVELY LICENSE CO TO USE DIABECELL IN AUSTRALIA, ARGENTINA AND NEW ZEALAND ONCE FDA APPROVED​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-25T10:59:00.000+02:00",
    "crawled": "2018-01-25T13:12:49.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "living",
        "cell",
        "technology",
        "ltd",
        "agreed",
        "sell",
        "shareholding",
        "diatranz",
        "otsuka",
        "limited",
        "otsuka",
        "pharmaceutical",
        "factory",
        "co",
        "dol",
        "sign",
        "mou",
        "exclusively",
        "license",
        "co",
        "use",
        "diabecell",
        "australia",
        "argentina",
        "new",
        "zealand",
        "fda",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}